Kevin Heller, MD, has been named chief medical officer of Tallac Therapeutics, a biopharmaceutical company using innate and adaptive immunity to fight cancer.
Dr. Heller joins Tallac from Jasper Therapeutics, where he served as executive vice president of research and development. Prior to that, he was the chief medical officer for NextCure, according to a Jan. 19 release.
Dr. Heller got his start in the biopharmaceutical industry at Bristol Myers Squibb, where he eventually became global lead for oncology search and evaluation. He went on to serve as senior medical director for AstraZeneca and vice president and head of antibody clinical development at Incyte.